… Different routes of administration of effective and safe drugs increase flexibility and efficiency…
Rolapitant IV contains the synthetic surfactant polyoxyl 15 hydroxystearate [26, 31], and HTX…

… to rolapitant or placebo × 1 on day 1. A significantly higher proportion of patients in the
rolapitant group as compared with the placebo group had CR in the delayed phase (primary effect …

… Rolapitant is a highly selective NK1-RA characterized by … Citation17 Rolapitant also differs
from aprepitant and … to obtain the maximum efficacy in the prophylaxis of CINV. Citation32 …

… Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and
vomiting after administration of moderately emetogenic chemotherapy or anthracycline and …

… There are no clinical studies evaluating the efficacy of IV aprepitant/HTX-019 and IV rolapitant
as the approval of these agents was based primarily on demonstrating pharmacokinetic …

… Prevention of chemotherapy induced nausea and vomiting (… The purpose was to evaluate
episodes of nausea, vomiting, … plus rolapitant was given for CINV prophylaxis during PTCy …

… , CR rates were greater with rolapitant than with active control in the … rolapitant also support
the antiemetic efficacy of a substance P/neurokinin-1 receptor antagonist for the prevention of …

… prophylaxis before chemotherapy. We aim to assess chemotherapy-induced nausea and
vomiting … The Rolapitant tablets are smaller than the Aprepitant one and were preferred in case …

… for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
in … This article reviews therapeutic efficacy and tolerability data relating to the use of (fos)…

… The primary efficacy endpoint was complete response (no emesis/no rescue) during the …
have acknowledged NEPA and rolapitant as effective agents for decreasing nausea, they also …